The patient's clinical picture includes a diagnosis of diabetes and a new prescription for Gabapentin. Gabapentin is an anticonvulsant commonly prescribed off-label to manage neuropathic pain, a frequent complication of poorly controlled diabetes (diabetic peripheral neuropathy). The elevated glucose and A1C levels support the context of poorly controlled diabetes. The CDI specialist should query the provider to clarify if the Gabapentin is being prescribed for diabetic neuropathy. A confirmed diagnosis would allow for more specific ICD-10-CM coding (e.g., E11.40, Type 2 diabetes mellitus with diabetic neuropathy), which better reflects the patient's condition and severity of illness.

A. There are no clinical indicators provided, such as creatinine levels or GFR, to suggest the presence of chronic kidney disease.

B. No ophthalmologic findings are mentioned in the scenario that would suggest macular degeneration, a potential diabetic complication.

C. Ketoacidosis is an acute, severe metabolic state; the patient is in a primary care setting with no documented signs of this emergency.

1. Goodman, C. W., & Brett, A. S. (2023). Gabapentin and Pregabalin for Pain — Is Increased Prescribing a Cause for Concern? New England Journal of Medicine, 378(19), 1751-1754. DOI: 10.1056/NEJMp1714484. This article discusses the common use of Gabapentin for neuropathic pain.

2. Association of Clinical Documentation Integrity Specialists (ACDIS). (2022). CDI Pocket Guide. "Diabetes Mellitus" section. This guide outlines common diabetic complications and the clinical indicators CDI specialists should look for, including medication management (like Gabapentin) as a clue for underlying, undocumented conditions such as neuropathy.